Novartis wins big in head-to-head Eylea matchup, setting up a looming market feud with Regeneron
Novartis investigators went head-to-head with Regeneron’s blockbuster Eylea in two large Phase III studies. And they scored, scooping up promising top-line results and setting up …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
